Impulse control disorder: patients with pituitary adenomas and dopaminergic agonists
Main Article Content
Keywords
Disruptive, Impulse Control, and Conduct Disorders, Adenoma, Prolactinoma, Dopamine Agents
Abstract
Background: Impulse control disorder suggests a fronto-striatal dysfunction that impairs executive metacognitive abilities, as a result of dopamine receptor activation. Dopaminergic agonists serve as adjuvant therapy in pituitary adenomas.
Objective: To analyze the frequency of impulse control disorder in patients with pituitary adenomas treated with dopaminergic agonists.
Methods: Cross-sectional analytical study; ≥ 18 years old, diagnosed with pituitary adenoma, and receiving dopaminergic agonist treatment. The Barratt Impulsiveness Scale (BIS-11) was used. Proportions were compared using Chi-square; means with the Student’s t-test, Pearson´s correlation for the strength of the association between each subscale. Odds ratios (OR) were estimated for risk calculations. Statistical significance was set at p ≤ 0.05.
Results: Forty patients were studied, 50% female, with an average age of 42.32 years. According to the Barratt Impulsivity Scale (BIS-11), 40% showed cognitive impairment, 27.5% showed motor impulsivity, and 7.5% exhibited unplanned impulsivity. In total, 12.5% of the population tested positive. Seventy-five percent had a lower accumulated dose (less than 500 mg), with an average of 248.4 milligrams, and 60% had been on treatment for more than 2 years.
Conclusions: A 12.5% incidence of impulsivity was observed based on the total BIS-11 score, with a 19-fold higher risk in women, and a tendency toward microprolactinoma presence.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text rev. Arlington (VA): American Psychiatric Publishing; 2022.
2. Inder WJ, Jang C. Treatment of prolactinoma. Medicine (Kaunas) 2022;58(8):1095.
3. Stanford MS, Mathias CW, Dougherty DM, et al. Fifty years of the Barratt Impulsiveness Scale: An update and review. Pers Individ Dif [Internet]. 2009;47(5):385–95. Disponible en: http:// homepages.se.edu/cvonbergen/files/2013/01/Fifty-Years-of-the-BarrattImpulsivenss-Scale_An-Update-and-Review.pdf 69.
4. Steinberg L, Sharp C, Stanford MS, et al. New tricks for an old measure: the development of the Barratt Impulsiveness Scale- Brief (BIS-Brief). Psychol Assess. 2013 Mar;25(1):216-26. doi: 10.1037/a0030550. Epub 2012 Nov 12. PMID: 23148649.
5. N, Cosi S, Lorenzo-Seva U, Vigil-Colet A. Stability of the factor structure of Barrat’s Impulsivity Scales for children across cultures: a comparison of Spain and Colombia. Psicothema. 2010 Nov;22(4):983-9. PMID: 21044542.
6. Fossati A, Barratt ES, Acquarini E, Di Ceglie A. Psychometric properties of an adolescent version of the Barratt Impulsiveness Scale-11 for a sample of Italian high school students. Percept Mot Skills. 2002 Oct;95(2):621-35. doi: 10.2466/ pms.2002.95.2.621. PMID: 12434861.
7. Salvo G L, Castro S A. Confiabilidad y validez de la escala de impulsividad de Barratt (BIS-11) en adolescentes. Rev chil neuro-psiquiatr [Internet]. 2013;51(4):245–54. Disponible en: http://dx.doi.org/10.4067/s0717-92272013000400003.
8. Reise SP, Moore TM, Sabb FW, et al. The Barratt Impulsiveness Scale-11: reassessment of its structure in a community sample. Psychol Assess [Internet]. 2013;25(2):631–42. Disponible en: http://dx.doi.org/10.1037/a0032161.
9. Dogansen SC, Cikrikcili U, Oruk G, et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: A cross-sectional multicenter study. J Clin Endocrinol Metab [Internet]. 2019; 104(7):2527– 34. Disponible en: http:// dx.doi.org/10.1210/jc.2018-02202.
10. Hamblin R, Karavitaki N. Impulse Control Disorders in patients with pituitary tumors treated with dopamine agonists: A systematic review. Arch Med Res [Internet]. 2023;54(8):102910. Disponible en: http://dx.doi.org/10.1016/j.arcmed.2023.102910
11. Almalki MH, Alsuraikh MA, Almalki E, et al. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary [Internet]. 2024;27(2):197–203. Disponible en: http://dx.doi.org/10.1007/ s11102-024-01383-2
12. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol. 1995;51(6):768-774. PubMed
13. Lau JH, Jeyagurunathan A, Shafie S, et al. The factor structure of the Barratt Impulsiveness Scale (BIS-11) BMC Psychiatry. 2022;22:226. BioMed Central
14. Kapitány-Fövény M, Túry F, Sulyok S, et al. The 21-item Barratt Impulsiveness Scale Revised (BIS-R-21): alternative three-factor model including cognitive impulsivity. J Behav Addict. 2020;9(2):225-246.
15. RehabMeasures Database. Barratt Impulsiveness Scale (BIS- 11). 2023. (Descripción, tiempo de administración). Shirley Ryan AbilityLab
16. Beccuti G, Guaraldi F, Natta G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest [Internet]. 2021;44(8):1699–706. Disponible en: http://dx.doi.org/10.1007/s40618-020-01478-0.
17. Ozdeniz Varan E, Gurvit H. Effect of dopaminergic therapy on impulse control disorders in patients with a prolactinoma. Cogn Behav Neurol [Internet]. 2023;36(1):1–8. Disponible en: http://dx.doi.org/10.1097/WNN.0000000000000320
18. Patel SA, Frick KM, Newhouse PA, Astur RS. Estradiol effects on spatial memory in women. Behav Brain Res. 2022 Jan 24;417:113592. doi: 10.1016/j.bbr.2021.113592. Epub 2021 Sep 22. PMID: 34560131; PMCID: PMC8578444.
19. Pletzer B, Bodenbach H, Hoehn M, Hajdari L, Hausinger T, Noachtar I, Beltz AM. Reproducible stability of verbal and spatial functions along the menstrual cycle. Neuropsychopharmacology. 2024 May;49(6):933-941. doi: 10.1038/s41386-023-01789-9. Epub 2024 Jan 24. PMID: 38267632; PMCID: PMC11039678.
20. Ávila-Varela DS, et al. Whole-brain dynamics across the menstrual cycle: the role of hormonal fluctuations and age in healthy women. npj Women’s Health. 2024; Article: s44294-024-00012-4. doi:10.1038/s44294-024-00012-4.
21. Pletzer B, Bodenbach H, Hoehn M, et al. Reproducible stability of verbal and spatial functions along the menstrual cycle. Neuropsychopharmacology. 2024;49(6):933–941. doi:10.1038/ s41386-023-01789-9.
22. Jang D, Zhang J, Elfenbein HA. Menstrual cycle effects on cognitive performance: A meta-analysis. PLOS ONE. 2025; 20(3):e0318576. doi:10.1371/journal.pone.0318576.
23. Ioachimescu AG, Fleseriu M, Hoffman AR, et al. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol [Internet]. 2019 [citado el 3 de febrero de 2022];180(1):31–40. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30400048/
24. Lin TY, Hanna J, Ishak WW. Psychiatric Symptoms in Cushing’s Syndrome: A Systematic Review. Innov Clin Neurosci. 2020 Jan 1;17(1-3):30-35. PMID: 32547845; PMCID: PMC7239565.)
25. Hinojosa-Amaya JM, Johnson N, González-Torres C, et al. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Front Endocrinol (Lausanne). 2020 Oct 27;11:579606. doi: 10.3389/fendo.2020.579606. PMID: 33193096; PMCID: PMC7652723.
26 Ke X, Wang L, Chen M, Liu S, Yu N, Duan L, et al. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross-sectional study. BMC Endocr Disord [In¬ternet]. 2022;22(1):97. Disponible en: http://dx.doi.org/10.1186/ s12902-022-01009-3
27. Barabash N, Tykhonova T, Kanishcheva O. Current and Perspective Approaches to the Treatment of Prolactinomas. AML [Internet]. 2023 Jul. 31 [cited 2025 Apr. 3];30(2):165-76. https:// doi.org/10.15388/Amed.2023.30.2.1
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.